Our Pharmacogenomic (PGx) reports are among the best in the world for its comprehensiveness, usability, and readability - for both patients and doctors. Our reports are easy to access, read and understand. They include result sources, relative importance of results and genes tested, as well as treatment recommendations and common signs and symptoms. Our reports include an easy to read and understand “summary of results”, as well as a very detailed report that includes a full bibliography of scientific sources.

The Xeomics pharmacogenomics (PGx) report is the most comprehensive in the world, covering more than 500 drugs, 1060 genes and 2725 markers.

XMPS currently produces 7 general reports: Metabolic, Oncology, Cardiovascular, Colorectal cancer, Prostate cancer, Wellbeing, and Pharmacogenomic (PGx). Additional reports can be easily supported upon request.

XPMS currently produces 36 clinical reports for single gene implicated in familial rare diseases in a wide range of anatomy groupings. Additional gene types can be easily supported upon request.

XPMS is designed to evolve with new scientific evidence, guideline updates, and emerging gene–drug interactions. XPMS is a continuously updated decision-support system that keeps clinicians ahead of the curve.

We can reprocess the genetic data in the future as genetic marker research is updated, thus providing “lifetime of care” to patients.

We have a single pipeline able to handle multiple data sources, i.e. from WGS, WES, and microarray genotyping. We can thus provide our customers with any depth of genomic data coverage that they may require.